---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-23-000048"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:13:53.719128+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Supernus Q2 total revenues down 20% to $135.5M; Qelbree sales up 179%

## Summary
- GAAP operating loss of $17.6M vs income of $11.3M in Q2 2022; net loss $0.8M ($0.02 loss per share).
- Qelbree net sales $31.0M (+179% YoY), GOCOVRI $28.8M (+17%); Trokendi XR fell 73% to $19.3M on generic erosion.
- Non-GAAP adjusted operating earnings of $10.0M in Q2 vs $37.6M a year ago; six-month adjusted earnings $40.5M.
- Full-year 2023 guidance reaffirmed: revenues $580–620M, GAAP operating loss ($30)–($10)M, non-GAAP op earnings $75–100M.
- Cash and marketable securities $189.1M at June 30; completed $402.5M convertible note and $93M credit line repayments.

## SEC filing metadata
- accession: 0001356576-23-000048
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000048/0001356576-23-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000048/supn-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-23-000048
- JSON: https://secwatch.observer/filing/0001356576-23-000048.json
- Plain text: https://secwatch.observer/filing/0001356576-23-000048.txt

## Key facts
- Earnings Releases
  SUPERNUS PHARMACEUTICALS, INC. reported the second quarter ended June 30, 2023 results: revenue $135.5 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $135.5 million
  - Result: reported results
  source text: expects to have data in the first half of 2024. Financial Highlights Total revenues For the three months ended June 30, 2023, total revenues and total net product sales were $135.5 million and $128.3 million, respectively, compared to total revenues and total net product sales of $170.1 million and $165.5 million for the same periods in 2022. For the six months
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000048/0001356576-23-000048-index.htm
- Earnings Releases
  SUPERNUS PHARMACEUTICALS, INC. reported the first six months of 2023 results: revenue $289.3 million.
  - Period: the first six months of 2023
  - Revenue: $289.3 million
  - Result: reported results
  source text: Total revenues of $289.3 million in the first six months of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000048/0001356576-23-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.